XML 37 R25.htm IDEA: XBRL DOCUMENT v3.25.1
Stockholders’ Equity (Tables)
3 Months Ended
Mar. 31, 2025
Stockholders’ Equity [Abstract]  
Schedule of Changes in Options

A summary of the changes in options during the three months ended March 31, 2025 is as follows:

 

   Number of
Options
   Weighted
Average
Exercise
Price
Per
Share
   Weighted
Average
Remaining
Contractual
Term
(Years)
   Aggregate
Intrinsic
Value
 
Outstanding and expected to vest at December 31, 2024   12,263,017   $16.61    6.01   $
        -
 
Granted   203,567   $0.30    

-

   $  
Cancelled   (1,207,657)  $17.34    -   $- 
Outstanding at March 31, 2025   11,258,927   $16.24    6.46   $
-
 
Options exercisable at March 31, 2025   8,748,097   $19.02    6.02   $
-
 
Schedule of the Changes in Outstanding Warrants

A summary of the changes in outstanding warrants during the three months ended March 31, 2025 is as follows:

 

   Number of
Shares
   Weighted
Average
Exercise
Price
Per
Share
 
Outstanding Warrants at December 31, 2024   1,382,613   $17.02 
Expired   (509,705)   
-
 
Outstanding at March 31, 2025   872,908   $29.25 
Warrants Vested at March 31, 2025   865,033   $29.28 
Schedule of Stock-Based Compensation Expense

The following table summarizes the components of stock-based compensation expense which includes restricted stock, stock options, and warrants in the unaudited consolidated statements of operations for the three months ended March 31, 2025 and 2024 (rounded to nearest $00):

 

   Three Months
Ended
March 31,
2025
   Three Months
Ended
March 31,
2024
 
Research and development  $1,067,300   $1,699,300 
General and administrative   3,410,700    6,596,200 
Total  $4,478,000   $8,295,500